LivaNova Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
3,300
- Stock Symbol
-
LIVN
- Investments
-
20
- Share Price
-
$90.78
- (As of Friday Closing)
LivaNova General Information
Description
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Contact Information
Website
www.livanova.comCorporate Office
- 20 Eastbourne Terrace
- London W2 6LG
- England, United Kingdom
Corporate Office
- 20 Eastbourne Terrace
- London W2 6LG
- England, United Kingdom
LivaNova Stock Performance
As of 20-Nov-2026, LivaNova’s stock price is $90.78. Its current market cap is $5B with 55.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $90.78 | $92.11 | $53.48 - $99.38 | $5B | 55.1M | 686K | $3.58 |
LivaNova Financials Summary
As of 30-Sep-2026, LivaNova has a trailing 12-month revenue of $1.51B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 4,049,983 | 3,200,346 | 2,848,099 | 3,174,278 |
| Revenue | 1,506,914 | 1,388,053 | 1,253,437 | 1,153,545 |
| EBITDA | 202,552 | (130,845) | 172,449 | 16,471 |
| Net Income | 196,063 | (242,471) | 63,234 | 17,546 |
| Total Assets | 2,713,124 | 2,606,053 | 2,506,389 | 2,429,563 |
| Total Debt | 357,071 | 433,772 | 676,773 | 640,404 |
LivaNova Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
LivaNova Comparisons
Industry
Financing
Details
LivaNova Competitors (25)
One of LivaNova’s 25 competitors is Medtronic, a Corporation company based in Minneapolis, MN.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Medtronic | Corporation | Minneapolis, MN | ||||
| Boston Scientific | Corporation | Marlborough, MA | ||||
| Integra LifeSciences Holdings | Corporation | Princeton, NJ | ||||
| Penumbra | Formerly VC-backed | Alameda, CA | ||||
| Edwards Lifesciences | Corporation | Irvine, CA |
LivaNova Patents
LivaNova Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260207944-A1 | Systems and methods for obstructive respiratory event detection and stimulation therapy | Pending | 17-Jan-2025 | ||
| WO-2026155984-A1 | Systems for obstructive respiratory event detection and stimulation therapy | Pending | 17-Jan-2025 | ||
| WO-2026019898-A1 | Systems and methods for obstructive respiratory event detection | Pending | 17-Jul-2024 | ||
| US-20260021303-A1 | Systems and methods for obstructive respiratory event detection and stimulation therapy | Pending | 17-Jul-2024 | ||
| US-12569682-B2 | Automatic titration with defibrillation sensitivity compensation | Active | 17-Apr-2023 | A61N1/36114 |
LivaNova Signals
LivaNova Investments & Acquisitions (20)
LivaNova’s most recent deal was a Later Stage VC with ShiraTronics for . The deal was made on 11-Aug-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ShiraTronics | 11-Aug-2023 | Later Stage VC | Therapeutic Devices | ||
| Cadence Neuroscience | 28-Feb-2023 | Later Stage VC | Therapeutic Devices | ||
| ALung | 02-May-2022 | Merger/Acquisition | Other Devices and Supplies | ||
| ALung | 24-Aug-2021 | Later Stage VC | Other Devices and Supplies | ||
| Noctrix Health | 11-Jan-2021 | Later Stage VC | Therapeutic Devices |
LivaNova ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
22.12 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
LivaNova Exits (5)
LivaNova’s most recent exit was on 11-Jan-2021 from Noctrix Health. The exit was categorized as with 5 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Noctrix Health | 11-Jan-2021 | Completed |
|
||
| Ceribell | 25-Sep-2018 | Completed |
|
||
| Apnex Medical | 01-Apr-2014 | Completed |
|
||
| Cerbomed | 01-Sep-2012 | Completed |
|
||
| Cardiosolutions | 09-Jul-2012 | Early Stage VC | Completed |
|
LivaNova Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Livn Uk 2 Co | London, United Kingdom | 2015 | |
| Livn Irishco 2 Unlimited Company | Dublin, Ireland | 2015 | |
| Livanova Poland | Warsaw, Poland | 2011 | |
| Livanova Nederland | Amsterdam, Netherlands | 1988 | |
| Livanova Belgium | Zaventem, Belgium | 1968 |
LivaNova FAQs
-
When was LivaNova founded?
LivaNova was founded in 2015.
-
Where is LivaNova headquartered?
LivaNova is headquartered in London, United Kingdom.
-
What is the size of LivaNova?
LivaNova has 3,300 total employees.
-
What industry is LivaNova in?
LivaNova’s primary industry is Therapeutic Devices.
-
Is LivaNova a private or public company?
LivaNova is a Public company.
-
What is LivaNova’s stock symbol?
The ticker symbol for LivaNova is LIVN.
-
What is the current stock price of LivaNova?
As of 20-Nov-2026 the stock price of LivaNova is $90.78.
-
What is the current market cap of LivaNova?
The current market capitalization of LivaNova is $5B.
-
What is LivaNova’s current revenue?
The trailing twelve month revenue for LivaNova is $1.51B.
-
Who are LivaNova’s competitors?
Medtronic, Boston Scientific, Integra LifeSciences Holdings, Penumbra, and Edwards Lifesciences are some of the 25 competitors of LivaNova.
-
What is LivaNova’s annual earnings per share (EPS)?
LivaNova’s EPS for 12 months was $3.58.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process